EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
- Acquisition of Neogene Therapeutics completed
- Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
- NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs
Research & Development
- Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
- Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
- Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
- Power of cancer drugs may see boost by targeting newly ID'd pathway
- A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
- 500,000 missed out on blood pressure lowering drugs during pandemic
- Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease